Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Leukemia 24Breast Neoplasms 20Lymphoma 9Carcinoma, Non-Small-Cell Lung 8Lung Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Sarcoma 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Lymphoma, Large B-Cell, Diffuse 6Lymphoma, Follicular 6Leukemia, Myeloid, Acute 6Precancerous Conditions 5Multiple Myeloma 5Head and Neck Neoplasms 5Esophageal Neoplasms 5Congenital Abnormalities 5Colonic Neoplasms 5Central Nervous System Neoplasms 5Stomach Neoplasms 4Ovarian Neoplasms 4Lymphoma, Large-Cell, Anaplastic 4Colorectal Neoplasms 4Burkitt Lymphoma 4Adenocarcinoma Of Esophagus 4Wilms Tumor 3Rectal Neoplasms 3Prostatic Neoplasms 3Osteosarcoma 3Neuroectodermal Tumors, Primitive, Peripheral 3Neuroblastoma 3

Interventions

Temozolomide 1Microarray Analysis 1Dexamethasone 1DNA Methylation 1Calcium Dobesilate 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenoma, Chromophobe × Microarray Analysis × Clear all
NCT00601289 2020-07-31

Temozolomide in Treating Patients With Invasive Pituitary Tumors

Jonsson Comprehensive Cancer Center

Phase 2 Withdrawn
CNSEndocrine

Adenoma, Basophil, Adenoma, Chromophobe, Adenoma, Acidophil, Pituitary Neoplasms, Prolactinoma, Central Nervous System Neoplasms, Growth Hormone-Secreting Pituitary Adenoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡